DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
Rechercher
(titres de publication, de périodique et noms de colloque inclus)
2013-03-12 - Colloque/Présentation - poster - Anglais - 1 page(s)

Hambye Stéphanie , Ansseau Eugénie , Helvenstein Maxime , Carminati Aurélie, Vanden Eynde Jean-Jacques, Belayew Alexandra , Blankert Bertrand , "Analytical developments and biological evaluation (in Steinert desease) of Pentamidine and new analogs." in 7ième Matinée des Chercheurs, Mons, Belgique, 2013

  • Codes CREF : Analyse et contrôle pharmaceutique (DI3450), Chimie analytique (DI1314), Sciences pharmaceutiques (DI3400), Métabolisme (DI3223)
  • Unités de recherche UMONS : Biologie moléculaire (M122), Analyse pharmaceutique (M130), Chimie organique (S836)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé)

Abstract(s) :

(Anglais) Pentamidine is a well-known antiparasitic agent that was also recently described as a potential therapeutic agent in myotonic dystrophy type I (Steinert disease). Several analogs of this compound were synthetized in the laboratory of Organic Chemistry and are under several assessment procedures. The major aims processed in our research work are: i) To develop LC (HPLC and UPLC) methods with UV or fluorescence detection, and preextraction step using SPE or acetonitrile precipitation to establish pharmacokinetics of the new analogs and the parent drug in the rat. ii) To develop a rapid screening test to evaluate these new analogs in myotonic dystrophy. Three strategies are envisaged: microscopy, EMSA and competition dialysis.